Anavex Life Sciences Corp (AVXL)

[boi568]

"You repeatedly demonstrate that you are unable to see the big picture and only focus on rigid regulatory requirements that should be evaluated in light of an disease where current SOC is simply not acceptable."

You're giving his argument too much credit. There is no EMA "rigid regulatory requirement" that rules out Anavex's 2b/3 trial for size and duration, and no EMA requirement, either, for ADL to be used as a primary endpoint in an early AD trial. He is asserting regulatory preconditions that don't exist.